Home > Research > Publications & Outputs > The emerging role of fatty acid binding protein...

Research

Associated organisational units

Links

Text available via DOI:

Keywords

View graph of relations

The emerging role of fatty acid binding protein 5 (FABP5) in cancers

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Published

Standard

The emerging role of fatty acid binding protein 5 (FABP5) in cancers. / Warren, William George; Osborn, Myles; Yates, Andy et al.
In: Drug Discovery Today, Vol. 28, No. 7, 103628, 31.07.2023.

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Harvard

Warren, WG, Osborn, M, Yates, A, Wright, K & O'Sullivan, SE 2023, 'The emerging role of fatty acid binding protein 5 (FABP5) in cancers', Drug Discovery Today, vol. 28, no. 7, 103628. https://doi.org/10.1016/j.drudis.2023.103628

APA

Warren, W. G., Osborn, M., Yates, A., Wright, K., & O'Sullivan, S. E. (2023). The emerging role of fatty acid binding protein 5 (FABP5) in cancers. Drug Discovery Today, 28(7), Article 103628. https://doi.org/10.1016/j.drudis.2023.103628

Vancouver

Warren WG, Osborn M, Yates A, Wright K, O'Sullivan SE. The emerging role of fatty acid binding protein 5 (FABP5) in cancers. Drug Discovery Today. 2023 Jul 31;28(7):103628. Epub 2023 May 23. doi: 10.1016/j.drudis.2023.103628

Author

Warren, William George ; Osborn, Myles ; Yates, Andy et al. / The emerging role of fatty acid binding protein 5 (FABP5) in cancers. In: Drug Discovery Today. 2023 ; Vol. 28, No. 7.

Bibtex

@article{0744bd2e298545888a6e05e415f95d7d,
title = "The emerging role of fatty acid binding protein 5 (FABP5) in cancers",
abstract = "Fatty acid binding protein 5 (FABP5, or epidermal FABP) is an intracellular chaperone of fatty acid molecules that regulates lipid metabolism and cell growth. In patient-derived tumours, FABP5 expression is increased up to tenfold, often co-expressed with other cancer-related proteins. High tumoral FABP5 expression is associated with poor prognosis. FABP5 activates transcription factors (TFs) leading to increased expression of proteins involved in tumorigenesis. Genetic and pharmacological preclinical studies show that inhibiting FABP5 reduces protumoral markers, whereas elevation of FABP5 promotes tumour growth and spread. Thus, FABP5 might be a valid target for novel therapeutics. The evidence base is currently strongest for liver, prostate, breast, and brain cancers, and squamous cell carcinoma (SCC), which could represent relevant patient populations for any drug discovery programme.",
keywords = "cancer, tumour, fatty acid, lipid, fatty acid binding protein, FABP",
author = "Warren, {William George} and Myles Osborn and Andy Yates and Karen Wright and O'Sullivan, {Saoirse E}",
year = "2023",
month = jul,
day = "31",
doi = "10.1016/j.drudis.2023.103628",
language = "English",
volume = "28",
journal = "Drug Discovery Today",
issn = "1359-6446",
publisher = "Elsevier",
number = "7",

}

RIS

TY - JOUR

T1 - The emerging role of fatty acid binding protein 5 (FABP5) in cancers

AU - Warren, William George

AU - Osborn, Myles

AU - Yates, Andy

AU - Wright, Karen

AU - O'Sullivan, Saoirse E

PY - 2023/7/31

Y1 - 2023/7/31

N2 - Fatty acid binding protein 5 (FABP5, or epidermal FABP) is an intracellular chaperone of fatty acid molecules that regulates lipid metabolism and cell growth. In patient-derived tumours, FABP5 expression is increased up to tenfold, often co-expressed with other cancer-related proteins. High tumoral FABP5 expression is associated with poor prognosis. FABP5 activates transcription factors (TFs) leading to increased expression of proteins involved in tumorigenesis. Genetic and pharmacological preclinical studies show that inhibiting FABP5 reduces protumoral markers, whereas elevation of FABP5 promotes tumour growth and spread. Thus, FABP5 might be a valid target for novel therapeutics. The evidence base is currently strongest for liver, prostate, breast, and brain cancers, and squamous cell carcinoma (SCC), which could represent relevant patient populations for any drug discovery programme.

AB - Fatty acid binding protein 5 (FABP5, or epidermal FABP) is an intracellular chaperone of fatty acid molecules that regulates lipid metabolism and cell growth. In patient-derived tumours, FABP5 expression is increased up to tenfold, often co-expressed with other cancer-related proteins. High tumoral FABP5 expression is associated with poor prognosis. FABP5 activates transcription factors (TFs) leading to increased expression of proteins involved in tumorigenesis. Genetic and pharmacological preclinical studies show that inhibiting FABP5 reduces protumoral markers, whereas elevation of FABP5 promotes tumour growth and spread. Thus, FABP5 might be a valid target for novel therapeutics. The evidence base is currently strongest for liver, prostate, breast, and brain cancers, and squamous cell carcinoma (SCC), which could represent relevant patient populations for any drug discovery programme.

KW - cancer

KW - tumour

KW - fatty acid

KW - lipid, fatty acid binding protein

KW - FABP

U2 - 10.1016/j.drudis.2023.103628

DO - 10.1016/j.drudis.2023.103628

M3 - Journal article

VL - 28

JO - Drug Discovery Today

JF - Drug Discovery Today

SN - 1359-6446

IS - 7

M1 - 103628

ER -